Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. (Nasdaq: PYXS) is a clinical-stage biopharmaceutical company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, with a lead focus on recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). This news page aggregates company-issued updates, press releases, and other coverage related to Pyxis Oncology’s oncology pipeline and corporate activities.
Readers can find announcements on preliminary and updated clinical data for micvotabart pelidotin (MICVO), the company’s first-in-concept ADC targeting extradomain-B of fibronectin in the tumor extracellular matrix. News items include results from Phase 1 monotherapy and Phase 1/2 combination studies in R/M HNSCC and other advanced solid tumors, as well as translational findings on MICVO’s three-pronged mechanism of action involving direct tumor cell killing, bystander effects, and immunogenic cell death.
In addition to clinical trial readouts, this feed features business and financial updates such as quarterly results, cash runway commentary, milestone payments from collaboration and license agreements, and information on royalty-related transactions. Corporate developments, including inducement equity grants, governance matters, and participation in investor and industry conferences, are also reflected in Pyxis Oncology’s news flow.
For investors, analysts, and others following PYXS, the news stream offers a consolidated view of how the company is advancing MICVO in monotherapy and in combination with pembrolizumab under a Clinical Trial Collaboration Agreement with Merck, as well as how it positions itself within the broader field of ADC-based cancer therapeutics. Regularly reviewing this page can help users track key clinical milestones, scientific presentations, and corporate disclosures that shape the company’s oncology development story.
Pyxis Oncology (NASDAQ: PYXS) announced a leadership transition effective February 3, 2026: Thomas Civik, a long-standing board member, is appointed Interim CEO after Lara S. Sullivan, M.D., stepped down as President, CEO and CMO. The Board has launched a structured search for a permanent CEO.
The company said its clinical team will continue ongoing trials without interruption; lead program MICVO remains in Phase 1 monotherapy and Phase 1/2 combo studies with pembrolizumab.
Pyxis Oncology (Nasdaq: PYXS) said management will participate in two investor conferences in November 2025: a Guggenheim Healthcare Innovation fireside chat in Boston on November 10, 2025 at 2:30 p.m. ET and a Stifel Healthcare fireside chat in New York on November 11, 2025 at 4:00 p.m. ET.
Live webcasts and replays of both fireside chats will be available on Pyxis Oncology’s Events & Presentations page in the Investor Relations section of the company website.
Pyxis Oncology (NASDAQ: PYXS) reported preliminary Phase 1 data for micvotabart pelidotin (MICVO) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) as of Nov 3, 2025. Key efficacy: 46% confirmed ORR and 92% DCR for MICVO monotherapy at 5.4 mg/kg (18 patients, 13 evaluable); 71% confirmed ORR and 100% DCR for MICVO + pembrolizumab (7 patients at 3.6/4.4 mg/kg).
Safety: no Grade 5 events; notable Grade ≥3 TRAEs in monotherapy (56%) and discontinuations in 28% linked to patients with high bodyweight; combination arm showed no TRAE-driven discontinuations. Company sold royalty rights for $11M and expects cash runway into Q4 2026. Updated monotherapy data expected mid-2026; combination updates expected 2H26.
Pyxis Oncology (NASDAQ: PYXS) reported 3Q25 results and a program update on Nov 3, 2025. The company ended 3Q25 with $77.7 million in cash, cash equivalents and short-term investments and expects runway into the second half of 2026. Pyxis expects to report preliminary Phase 1 clinical data for micvotabart pelidotin (MICVO) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in 4Q25, covering monotherapy dose expansion (2L/3L arms) and combination dose escalation with KEYTRUDA under a Clinical Trial Collaboration Agreement with Merck.
Translational posters at ESMO and AACR-NCI-EORTC showed ctDNA reductions in the majority of 37 clinical samples and signals at the 5.4 mg/kg dose, supporting continued development.
Pyxis Oncology (NASDAQ: PYXS) will present translational data for micvotabart pelidotin (MICVO), a first-in-concept extracellular-cleaving ADC targeting EDB+FN, at ESMO 2025 (Oct 17-21) and AACR-NCI-EORTC Boston (Oct 22-26).
Key findings highlight a three-pronged mechanism—direct tumor cell killing, bystander killing, and immunogenic cell death—and report tumor microenvironment remodeling and immune activation. Observations included reductions in circulating tumor DNA tumor fraction in the vast majority of 37 clinical samples tested, with notable ctDNA TF decreases in HNSCC at the 5.4 mg/kg dose. Digital pathology features of stromal architecture may correlate with MICVO sensitivity.
Pyxis Oncology (Nasdaq: PYXS) appointed Alex Kane as Senior Vice President, Investor Relations & Capital Markets, effective October 9, 2025. Kane joins with 20 years of life‑science investor relations and equity capital markets experience, most recently at Guggenheim Securities.
His background includes investor relations and communications roles at Praxis Precision Medicines and PTC Therapeutics and prior leadership at W2O Group, Nasdaq, and Thomson Reuters. Kane holds an MBA in Finance and Entrepreneurship from NYU Stern and a BA in International Political Economy from Colorado College. Management highlights cite his experience with IPOs, secondary offerings, and investor engagement as relevant to advancing Pyxis Oncology’s clinical programs and upcoming milestones.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on antibody-drug conjugate therapeutics, has granted stock options to seven new employees under its 2022 Inducement Plan. The grants total 382,518 shares, with 261,268 shares vesting over four years and 121,250 shares vesting on December 31, 2025.
The stock options have a ten-year term and an exercise price of $2.22 per share, matching Pyxis Oncology's closing stock price on September 30, 2025. These grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing antibody-drug conjugate therapeutics, has announced its participation in three upcoming conferences in September 2025.
The company's CEO, Dr. Lara S. Sullivan, will participate in fireside chats at the 2025 Cantor Global Healthcare Conference on September 3 and the H.C. Wainwright Global Investment Conference on September 8. Additionally, Pyxis will present at the 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit on September 9.
Webcasts for the investor conference presentations will be available on the company's investor relations website.
Pyxis Oncology (Nasdaq: PYXS) reported Q2 2025 financial results and provided updates on its clinical programs. The company's lead antibody-drug conjugate (ADC) candidate, micvotabart pelidotin (MICVO), is advancing in clinical trials with preliminary data expected in H2 2025 and H1 2026.
Key financial highlights include $90.4 million in cash and investments, providing runway into H2 2026. Q2 revenues were $2.8 million from a milestone payment from Simcere, with a net loss of $18.4 million ($0.30 per share). R&D expenses increased to $17.1 million, while G&A expenses decreased to $5.4 million.
The company is progressing with two key clinical trials: a Phase 1 monotherapy study for head and neck cancer and a Phase 1/2 combination study with KEYTRUDA®, both showing promising potential in treating advanced solid tumors.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation antibody-drug conjugate therapeutics, has announced the granting of inducement stock options to four new employees. The company's Compensation Committee approved options to purchase 246,238 shares of common stock under the 2022 Inducement Plan.
The stock options are structured in two tranches: 181,238 options vest over four years with 25% vesting after one year and the remainder monthly over 36 months, while 65,000 options vest fully on December 31, 2025. All options have a ten-year term and an exercise price of $1.10 per share, matching Pyxis Oncology's closing stock price on June 30, 2025.